Aim Direct oral anticoagulants (DOACs) have shown noninferiority to warfarin for stroke
prevention in nonvalvular atrial fibrillation (AF) and a more promising safety profile …

Non-vitamin K oral anticoagulants, also known as direct-acting oral anticoagulants (DOACs),
have entered the market in 2008 with the expected breakthrough potential of circumventing …

Aims The objective was to compare major bleeding risk of direct oral anticoagulants
(DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication …

Direct oral anticoagulants (DOACs) have been marketed in the United States since 2010.
While numerous large-scale prospective phase 3 outcomes studies have documented the …

Direct oral anticoagulants (DOACs) have rapidly become the drug class of choice for
anticoagulation therapy in secondary care. It is known that gastrointestinal hemorrhage are …

Anticoagulant-associated adverse drug reactions in 2013–15 | Tidsskrift for Den norske
legeforening Skip to main content Toggle navigation Artikler Fagområder Utgaver Podkast …

ABSTRACT Introduction: Direct oral anticoagulants (DOACs) may be regarded as some of
the most successful innovations in recent times. These drugs which were specifically …

Purpose To report the use of direct oral anticoagulants (DOACs) for stroke prevention in
patients with atrial fibrillation in Scotland and advocate the standardisation of drug utilisation …

The presence of atrial fibrillation (AF), the most common sustained cardiac arrhythmia,
significantly increases the risk for stroke. Current guidelines recommend that the vitamin K …

Aims The aim of this study was to compare the clinical effectiveness and safety of direct oral
anticoagulants (DOACs) in patients with atrial fibrillation (AF) in routine clinical practice …